Taken together, our current observations lend further support for the putative role of miR-151a-3p and miR-221/222 and their (here confirmed) respective target-genes, CHL1 and ITGB3, in SSRI responsiveness, and possibly in the pathology of MDD. This evidence concerns the gene ITGB3 and major depressive disorder.